1 2	A Meta-analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation and Adverse Effects with Ivermectin Use in COVID-19 Patients
3	*Smruti Karale, MBBS ¹ ; *Vikas Bansal, MBBS, MPH ² ; Janaki Makadia, MBBS ³ ; Muhammad
4	Tayyeb, MD ⁴ ; Hira Khan, MBBS ⁵ ; Shree Spandana Ghanta, MBBS ⁶ ; Romil Singh, MBBS ² ;
5	Aysun Tekin, MD ² ; Abhishek Bhurwal, MD ⁷ ; Hemant Mutneja, MD ⁸ ; Ishita Mehra, MBBS ⁹ ;
6	Rahul Kashyap, MBBS, MBA ²
7	¹ Medical Graduate, Government Medical College Kolhapur, Kolhapur, India
8	² Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Rochester, MN, USA
9	³ Medical Graduate, GMERS Medical College Gotri, Vadodara, Gujarat, India
10	⁴ Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ, USA
11	⁵ Department of Neurology, Allegheny General Hospital, Pittsburgh, PA, USA
12	⁶ Department of Internal Medicine, St. Elizabeth's Medical Center, Boston, MA, USA
13	⁷ Department of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of
14	Medicine, New Brunswick, NJ, USA
15	⁸ Division of Gastroenterology, Cook County Hospital, Chicago, Illinois

⁹Department of Internal Medicine, North Alabama Medical Center, Florence, AL, USA

17 Corresponding Author:

18 Vikas Bansal, MBBS, MPH

- 19 Assistant Professor of Medicine
- 20 Division of Pulmonary Medicine and Critical Care
- 21 Mayo Clinic, Rochester, MN- 55905
- 22 Email: bansal.vikas@mayo.edu
- 23 Phone: 1-507-398-1595
- 24 Word count: Abstract: 300; Manuscript: 2981
- 25 Tables: 0 main, 8 supplemental
- 26 Figures: 5 main, 19 supplemental
- 27 **Conflicts of Interest:** None of the authors have reported any conflicts of interest.
- **Financial Support:** There is no financial disclosure related to this study.
- 29 Author Contribution: *Authors 1(SK) and 2(VB) contributed equally in defining the study
- 30 outline and manuscript writing. Data review and collection were done by HK, JM, SG, RS, SK,
- and MT; statistical analysis done by SK, VB, and AB. Quality assessment of studies was done by
- 32 AT, JM, HK, MT, SK, VB and GRADE quality rating was done by AB, HM and VB. Study
- design, distribution of Articles for critical review done by SK, VB and RK. Final approval was
- 34 received from all authors. SK and VB is the guarantor of the paper, taking responsibility for the
- 35 integrity of the work as a whole, from inception to published article.

36	Ackno	owledgment: We acknowledge Dr. Anant Mohan, Dr. Asma Asghar, Dr. José
37	Morge	enstern, Dr. Flavio Cadegiani, Dr. Morteza Niaee, Dr. Nasir Afsar, Dr. Nurullah Okumus,
38	Dr. Pa	blo Méndez-Hernández and Dr. Ravi Kirti for their correspondence and contribution.
39	Keyw	ords: Ivermectin, COVID-19, SARS-CoV-2, Mortality, ICU, Mechanical ventilation,
40	advers	se effect, Systematic Review, Meta-analysis
41	Highl	ights
42	What	We Already Know about This Topic
43	1.	COVID-19 is an ongoing global pandemic, for which Ivermectin has been tried on a
44		therapeutic and prophylactic basis.
45	2.	Results from several clinical trials and observational studies suggest that Ivermectin may
46		improve survival and clinical outcomes with a good safety profile when compared with
47		other treatments; however, the current evidence is limited
48	What	This Article Tells Us That Is New
49	1.	This systematic review and meta-analysis provide a summary of the latest literature on
50		the efficacy and safety of Ivermectin use for COVID-19.
51	2.	Based on our quantitative and qualitative analysis, we found that Ivermectin may be a
52		potentially useful adjuvant therapy in reducing mortality, the need for ICU admissions
53		and mechanical ventilation in COVID-19 patients.

54 List of abbreviations

- 55 **CDC:** Centers for Disease Control and Prevention
- 56 COVID-19: Coronavirus Disease 2019
- 57 **DNA:** Deoxyribonucleic Acid
- 58 **FDA:** Food and Drug Administration
- 59 FLCCC: Front line COVID-19 Critical Care
- 60 **ICU:** Intensive Care Unit
- 61 **IRB:** Institutional Review Board
- 62 NIH: National Institutes of Health
- 63 **RCT:** Randomized controlled trial
- 64 **RNA:** Ribonucleic Acid
- 65 **RT-PCR:** Reverse Transcription Polymerase Chain Reaction
- 66 **IMP:** Importin
- 67 SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2
- 68 WHO: World Health Organization

69 Abstract

Importance/Background: Despite the global healthcare's exhaustive efforts to treat COVID-19, we still do not have an effective cure for it. Repurposing Ivermectin, a known antiparasitic agent, for treating COVID-19 has demonstrated positive results in several studies. We aim to evaluate the benefit and risk of Ivermectin in COVID-19.

- 74 **Methods:** We conducted a systematic search for full-text manuscripts published from February
- 1, 2020 to March 27, 2021 that focused on efficacy and safety of Ivermectin therapy against
- 76 COVID-19. The primary outcomes were overall mortality, need for intensive care unit (ICU)
- admission; secondary outcomes were adverse effects, need for mechanical ventilation.
- 78 Random-effects models were used for all analysis.

79 **Results:** We included a total of 38 studies (n=15,002) in the qualitative analysis (Mortality

N=28, ICU admission= 8, Mechanical Ventilation= 10, Adverse events=28) and out of these, 30

studies (n=11,291) were included in the quantitative analysis (Mortality N=22, ICU admission=

- 5, Mechanical Ventilation= 9, Adverse events=17). In the mortality meta-analysis, odds of death
- 83 were lower in the Ivermectin-arm compared to the non-Ivermectin arm. (OR 0.39, 95% CI 0.22-
- $0.70; I^2 = 81\%$). Subgroup analysis of 12 randomized controlled trials with severity-based data
- showed mortality benefit overall (OR 0.33, 95% CI 0.15-0.72; $I^2=53\%$) and in the mild/moderate
- sub-group (OR 0.10, 95% CI 0.03-0.33; $I^2=0\%$). Benefit of Ivermectin in decreasing; the need
- for ICU admission (OR 0.48, 95% CI 0.17-1.37; $I^2=59\%$) and mechanical ventilation (OR 0.64,
- 88 95% CI 0.40-1.04; $I^2=17\%$) was not significant. The quantitative analysis of adverse effects with
- 89 Ivermettin use was inconclusive (OR 0.92, 95% CI 0.64-1.33; $I^2=14\%$).

- 90 **Conclusion:** Our meta-analysis suggests that Ivermectin could be an effective adjuvant therapy
- 91 in reducing mortality, particularly in patients with mild-moderate clinical presentation of
- 92 COVID-19. Trends of decreased need for ICU admissions and mechanical ventilation were
- observed but were not significant. The analysis for adverse effects was inconclusive.

94 Introduction

On March 11, 2020, the World Health Organization (WHO) declared COVID-19 disease 95 a global pandemic¹. Today, on April 29,2021, there are about >149 million confirmed cases 96 worldwide and >3 million deaths due to COVID-19². Patients infected with SARS-COV-2, the 97 causative Coronavirus, exhibit a spectrum of clinical presentations ranging from asymptomatic to 98 severely critical and multiple risk factors are involved in the prognosis of the disease³⁻⁸. To guide 99 decision-making for this multi-system disease⁸⁻¹⁷, a variety of treatment modalities have been 100 proposed and evaluated¹⁸⁻²³. However, the evidence for the risk-benefit ratio of most of these 101 treatments remains unclear. 102

Ivermectin has held an excellent safety record in humans as an antiparasitic agent for 103 over three decades²⁴. Apart from its established activity against several parasites, Ivermectin has 104 demonstrated antiviral activity against many RNA and DNA viruses in vivo and against a few in 105 vitro by targeting specific proteins²⁵. One such plausible mechanism against RNA viruses is the 106 107 inhibition of importin (IMP) α/β Integrase, thus blocking viral entry into the nucleus and the ensuing suppression of the cell's anti-viral response²⁵⁻²⁸. Moreover, it exhibited anti-bacterial, 108 anti-inflammatory, and anti-cancer effects^{24,29,30}. An Australian study demonstrated the 109 effectiveness of Ivermectin in inhibiting SARS-COV2 in-vitro³¹. Subsequently, several 110 111 Ivermectin-based clinical trials and observational studies conducted globally showed mostly positive results³²⁻³⁵. Some countries have incorporated this therapy in their COVID-19 112 guidelines³⁶⁻³⁹. Only a month after this authorization, Peru witnessed a record drop of 25% in 113 COVID-19 related mortality⁴⁰. 114

Dr. Satoshi Ōmura, who was among the scientists that won the Nobel prize for the
discovery of Ivermectin, highlighted the need to develop a drug that arrests the early stage of

7

117	viral replication in COVID-19 ⁴¹ . Repurposing Ivermectin, a low-cost drug may help bypass the
118	time and funds needed to develop and test novel therapies. The lack of robust evidence has been
119	a major hindrance in the large-scale approval of Ivermectin. The available studies are
120	methodologically diverse and mostly under-powered while few report conflicting results.
121	Therefore, we intend to systematically review the latest literature and plan to perform a meta-
122	analysis to overcome some of the individual study biases.
123	Methods:
124	Search Method and strategy
125	We conducted a comprehensive literature search for studies mentioning the use of
126	Ivermectin in COVID-19 from February 1, 2020 till March 27, 2021 (Figure 1). We screened all
127	titles and abstracts identified by preliminary search for eligible studies and manually searched
128	references of included articles for additional studies. Then we analyzed full-text manuscripts of
129	included studies according to the protocol of Systematic Review and Meta-Analysis (PRISMA)
130	guidelines.
131	Eligibility Criteria

We included studies reporting outcomes of mortality, ICU admission, mechanical ventilation, and adverse-effects with Ivermectin treatment against COVID-19. We excluded studies focusing on pregnant females, in- vitro studies, meta-analyses, case reports and case series <5 patients.

136 Study selection and data extraction

The extracted data was tabularized in Microsoft Excel with following parameters: author,
country of study, study design, number of patients, Ivermectin regimen, concomitant treatment,

139	efficacy outcomes and adverse effects. The included data was checked for accuracy by all
140	authors and disagreements were resolved through consensus and after input from a third
141	reviewer. IRB approval was exempted because data was extracted from publicly available
142	studies. We also analyzed raw data files of studies by Cadegiani ⁴² and Lima-Morales et al ⁴³ for
143	cases receiving Ivermectin; and Niaee et al ⁴⁴ for clinical severity data. In Cadegiani et al's
144	study ⁴² , we considered 'CG1' as control group because only this sample was demographically
145	comparable to the treatment group. Bernigaud et al.'s study ⁴⁵ was excluded because the
146	methodology and outcomes were poorly described. Additionally, we compiled all ongoing
147	clinical trials on Ivermectin from clinicaltrials.gov (e-table 8).

148 Outcomes

The primary outcome was defined as mortality benefit with Ivermectin therapy in
COVID-19 and need for ICU admission. The secondary outcomes were need for mechanical
ventilation and adverse effects of Ivermectin.

152 Statistical analysis

153 Primary and Secondary outcomes were quantitatively analyzed by Review Manager (RevMan) Version 5.4 for windows⁴⁶ and Comprehensive Meta-Analysis software package 154 (Biostat, Englewood, NJ, USA)⁴⁷ was used for qualitative-analysis. Random-effects model was 155 used for both⁴⁸. Raw data for outcomes and non-events from each study were used to calculate 156 crude odds ratio (OR) with 95% confidence intervals (CI) for each study. The Cochrane Q and I^2 157 statistics were calculated to assess heterogeneity between studies⁴⁸. $I^2 < 25\%$ were interpreted as 158 low-level heterogeneity⁴⁸. We performed subgroup analysis by study design to decrease inherent 159 selection bias in observational studies⁴⁸. Probability of publication bias was assessed with funnel 160 plot using Egger's tests⁴⁸ (e-figure 14-19). If there was statistical heterogeneity in results, further 161

sensitivity analysis was conducted to determine the source of heterogeneity by excluding each
 study. After significant heterogeneity was excluded, random-effects model was used for meta analysis. P-value <0.05 (2-sided) was considered statistically significant⁴⁸.

165 Risk of Bias and Quality assessment

166 Clinical trials were evaluated using Cochrane risk of bias $tool^{49}$ (e-table 2) and correlation of

trials tool⁵⁰ (e-table 3) was used for quality assessment. We used NIH quality assessment Tool

quality measures with estimates of treatment effects in meta-analyses of randomized controlled

169 for case series⁵¹ (e-table 4), case-control (e-table 5), or cohort studies (e-table 6). NIH quality

assessment tools were based on quality assessment methods, concepts, and other tools developed

171 by researchers in the Agency for Healthcare Research and Quality (AHRQ), Cochrane

172 Collaboration, USPSTF, Scottish Intercollegiate Guidelines Network, and National Health

173 Service Centre for Reviews and Dissemination, consulting epidemiologists and evidence-based

174 medicine experts, with adaptations by methodologists and NHLBI staff. We assessed the

175 certainty of evidence by using GRADE pro profiler⁵² (GRADE working group, McMaster

176 University and Evidence Prime Inc) at the outcome level (e-table 7).

177 **Results**

167

178 Study Characteristics

179 A total of 15002 patients from 38 articles^{32-35,42-44,53-83} (Ivermectin n=6669, No Ivermectin

n=8333) were included in qualitative analysis, 11291 patients from 30 studies (Ivermectin

181 n=2996, No Ivermectin n=8295) were included in quantitative synthesis (e-table 1, Figure 1).

182 Out of 24 trials, 19 were true RCTs (e-table 1, Figure 1). The remaining 14 studies were

183 observational and included 6 case-series (e-table 1, Figure 1). Out of 38, 16 articles were

- available as preprints and clinicaltrials.gov was used for data extraction for 2 trials^{76,84} (e-table
- 185 1, Figure 1). We only included the patients treated therapeutically in the study by Elgazzar et
- 186 al^{64} . Due to absence of informed consent, blinding and randomization, we considered
- 187 Veerapaneni et al's 83 study as case control study.
- 188 **Primary Outcomes**
- 189 Mortality
- 190 Meta-analysis
- 191 **Overall**
- 192 Total 22 studies reported mortality rate in patients receiving Ivermectin (252/2778) vs no-
- 193 Ivermectin therapy (1265/8038). The odds of mortality in the Ivermectin group were
- significantly lower compared to control group (OR 0.39, 95% CI 0.22-0.70, p=0.002; I²=81%)
- 195 (Figure 2A) but evidence was graded very low. In sensitivity analysis, we observed similar
- 196 mortality benefit with moderate heterogeneity after excluding study by Soto-Becerra et al^{82} (OR

197 0.36, 95% CI 0.22-0.58, p<0.001; I^2 =56%) (Figure 2B).

198 Subgroup analysis by study design

199 Subgroup: Clinical trials

We performed subgroup analysis of 15 clinical trials (RCTs N=12, Non-RCTs N=3) and observed similar mortality benefit (OR 0.32, 95% CI 0.15-0.65, p=0.002; I^2 =65%) (Figure 3A) but evidence was graded very low. On excluding Galan et al⁶⁶ for sensitivity analysis, benefit observed was more solid with moderate heterogeneity (OR 0.26, 95% CI 0.13-0.50, p<0.001; I^2 =46%) (e-figure 1)

205 Subgroup: RCTs

206	We analyzed clinical severity-based data in 12 RCTs. The odds of mortality were
207	lowered with Ivermectin in the overall group, with moderate heterogeneity (OR 0.33, 95% CI
208	0.15-0.72, p=0.005; I^2 =53%) Similar benefit was observed in the mild/moderate subgroup (OR
209	0.10, 95% CI 0.03-0.33, p=0.002; $I^2=0\%$). However, mortality benefit was not statistically
210	significant in the severe/critical subgroup (OR 0.53, 95% CI 0.23-1.23, p=0.14; I^2 =57% (Figure
211	3B). Certainty of evidence was moderate overall; however, it was high in mild/moderate and
212	moderate in severe/critical subgroup. Therefore, in mild/moderate COVID-19 patients,
213	Ivermectin could be used for reducing mortality.
214	In sensitivity analysis, after excluding Elgazzar et al ⁶⁴ from the severe/critical subgroup,
215	odds of mortality increased in the total group, with moderate heterogeneity (OR 0.43, 95% CI
216	0.21-0.90, p=0.02; I^2 =39%). The odds increased in the severe/critical subgroup, with no
217	heterogeneity (OR 0.84, 95% CI 0.49-1.43, p=0.53; $I^2=0\%$), but remained statistically
218	insignificant (e-figure 2).
219	Observational studies

Mortality benefit was not statistically significant in subgroup of 7 observational studies (OR 0.61, 95% CI 0.30-1.22, p=0.16; $I^2=74\%$) (Figure 3C) and evidence was graded very low. On excluding Soto-Becerra et al⁸² in sensitivity analysis, we observed statistically significant mortality benefit (OR 0.51, 95% CI 0.34- 0.77, p=0.001; $I^2=0\%$) (e-figure 3).

224 Subgroup analysis for hospitalized patients

225 **Overall**

- 226 Subgroup analysis for hospitalized patients (studies N=15) showed mortality benefit with
- high heterogeneity (OR 0.48, 95% CI 0.28-0.83, p=0.009; $I^2=75\%$) (e-figure 4). After excluding
- 228 Soto-Becerra et al⁸² in sensitivity analysis, we observed similar benefit with acceptable
- heterogeneity (OR 0.43, 95% CI 0.26-0.71, p=<0.01; I^2 =48%) (e-figure 5).

230 Subgroup: Inpatient RCTs

- Analysis of RCTs (N=8) with only hospitalized patients showed similar mortality benefit
- 232 (OR 0.36, 95% CI 0.15-0.87, p=0.02; $I^2=67\%$) (e-figure 6). Evidence was graded moderate.
- After excluding Galan et al⁶⁶ in sensitivity analysis, mortality benefit with moderate

heterogeneity was seen (OR 0.28, 95% CI 0.11-0.73, p=0.009; $I^2 = 59\%$) (e-figure 7).

235 Subgroup: Inpatient Observational studies

Mortality benefit was also seen in 6 observational studies with only hospitalized patients, with high heterogeneity (OR 0.63, 95% CI 0.31-1.29, p=0.21; $I^2=77\%$) (e-figure 8). Evidence was graded very low. In sensitivity analysis, after excluding Soto-Becerra et al⁸² significant mortality benefit was seen with low heterogeneity (OR 0.51, 95% CI 0.32-0.81, p=0.005; $I^2=10\%$) (e-figure 9).

241 Qualitative Analysis for mortality

Pooled analysis of 28 studies out of 38 studies, yielded a rate of 3.5%, 95% CI 1.8-6.6; I²=95.1% (e-figure 10).

244 Need for ICU admission

245 Meta-analysis

In 5 studies (out of 30), 27/263 in the Ivermectin arm, 52/322 in the control arm needed ICU admission. Benefit with Ivermectin was not statistically significant (OR 0.48, 95% CI 0.17-1.37, p=0.17; I^2 =59%) (Figure 4A). Evidence was graded very low. In sensitivity analysis, after excluding Galan et al⁶⁶ we observed statistically significant benefit (OR 0.32, 95% CI 0.11-0.92, p=0.03; I^2 =27%) (Figure 4B). Based on low grading of evidence and observed low-moderate heterogeneity in analysis, Ivermectin may be helpful in decreasing need for ICU admission. Further validation with well-designed pragmatic platform trials is needed.

253 Qualitative Analysis

Pooled ICU admission rate obtained from 8 studies (out of 38) was 5.4%, 95% CI 1.9-

255 14.7; I²=91.9% (e-figure 11).

256 Secondary Outcomes

257 Need for Mechanical Ventilation

258 Meta-analysis

- 259 Overall, 9 studies documented the need for mechanical ventilation. 62/995 patients
- receiving Ivermectin and 81/787 patients in the control arm required mechanical ventilation. The
- benefit of Ivermectin was statistically insignificant (OR=0.64, 95%CI 0.40-1.04, p=0.07;
- 262 $I^2=17\%$) (Figure 4C). Evidence was graded very low. On excluding Galan et al⁶⁶ in sensitivity
- analysis, benefit observed was statistically significant with low heterogeneity (OR 0.55, 95% CI
- 264 0.33-0.93, p=0.03; I²=9%) (Figure 4D). Although the evidence was low, Ivermectin may confer

265	significant protection against the need for mechanical ventilation. Hence, we would suggest
266	considering Ivermectin with bedside clinician's judgement.

267 **Qualitative Analysis**

- The rate of need for mechanical ventilation based on 10 studies (out of 38) was 4.4%,
- 269 95% CI 1.6-11.1; I²=88.8% (e-figure 12).
- 270 Adverse events

271 Meta-analysis

- A total of 17 studies reported data for rate of adverse-events in the Ivermectin-arm
- 273 (245/973) vs control group (234/945). We did not find an association between Ivermectin and
- rate of adverse events as compared to controls (OR 0.92, 95% CI 0.64- 1.33, p=0.67; $I^2=14\%$).
- 275 (Figure 5A) but evidence was graded very low. In sensitivity Analysis, after excluding Mahmud
- et al⁷⁶ incidence of adverse effects with Ivermectin was similar to that of the control group but
- 277 was not conclusive (OR 0.85, 95% CI 0.62-1.16, p=0.31; $I^2=0\%$) (Figure 5B).

278 **Qualitative Analysis**

279 A total of 28 studies (out of 38) yielded a pooled rate of 8.1%, 95% CI 4.2-14.8; 280 $I^2=93.5\%$ (e-figure 13).

281 **Discussion**

Our meta-analysis suggests that Ivermectin may improve survival in COVID-19 patients and reduce the need for admission to the ICU and mechanical ventilation. However, its relation to the incidence of adverse effects is inconclusive. Further, our qualitative analysis indicates that Ivermectin treatment is linked to lower death rate and better clinical outcomes with a low

incidence of adverse effects. The inherent methodological limitations and risk of bias conferred
variable evidence grading in the findings in various patient outcomes.

288 Mortality

289	Our findings are corroborated by other meta-analyses done by Padhy 85 (studies N=3),
290	Hill ⁸⁶ (studies N=6), Lawrie ⁸⁷ (studies N=5), Nardelli ⁸⁸ (studies N=7), Kow ⁸⁹ (studies N=6),
291	Bryant et al ⁹⁰ (studies N=13) and the BIRD group ⁹¹ (studies N=13) which found Ivermectin to
292	be conclusively linked to lower mortality when compared to usual treatment. A network meta-
293	analysis ⁹² (studies N=2) reported that Ivermectin was linked to lower mortality with a very close
294	statistical significance. Casteneda-Sabogal et al's meta-analysis93 (studies N=6) found no
295	conclusive association of Ivermectin with reduced mortality. Of note, the above two studies
296	reported low or very low certainty of evidence ^{92,93} . Our sample size exceeds (studies N=22) that
297	of all the aforementioned studies.
298	Our pooled analysis resulting in a low mortality rate of 3.5% with use of Ivermectin
299	reiterates its positive impact in lowering mortality in COVID-19 patients. For a valid
300	comparison, it is important to factor in the time window during which the individual studies were
301	conducted. Most studies recorded their data in the II&III quarter of 2020 when mortality rates
302	with various treatments were often higher in respective countries ⁹⁴ .

303 Need for ICU admission and Mechanical Ventilation

304 Due to the small number of studies and their small individual sample size, benefit with 305 Ivermectin in reducing ICU admissions or mechanical ventilation cannot be concluded with 306 confidence. In our pooled analysis, we observed significantly lower rates for ICU admission 307 (5.43%) and mechanical ventilation (4.36%) in Ivermectin-treated patients when compared to

other treatments⁹⁵⁻⁹⁷. It must be noted that our pooled analysis mostly included mild/moderate
patients, which may skew the results in favor of Ivermectin.

310 Adverse events

Our analysis for adverse events was inconclusive. We noticed that most adverse events 311 312 were non-serious: nausea, vomiting, abdominal pain, diarrhea, pruritus, lethargy, vertigo, 313 tingling, numbness, anxiety, mild hyperglycemia etc. Yet, very few patients reported serious events like organizing pneumonia, hyponatremia, erosive esophagitis, infections/infestations. 314 Erosive esophagitis was attributed to concomitant use of Doxycycline⁷⁶; hyponatremia⁷⁴ was 315 likely from SIADH-a rare COVID-19 complication⁹⁸. Only Lopez-Medina et al⁷⁵, that used a 316 high Ivermectin dose of 1500ug/Kg over 5 days, reported drug discontinuation due to adverse-317 318 reactions. Given the non-serious nature of most adverse-reactions, and a low pooled rate of 8.1% in comparison to other available treatments^{23,99,100}, we suggest that Ivermectin was generally well 319 tolerated. 320

321 Strengths

To our knowledge, this is the largest patient sample size for a systematic review and 322 meta-analysis on the use of Ivermectin for COVID-19. This study integrates data of 323 324 approximately 15,000 patients from 38 studies conducted globally. Additionally, we obtained robust evidence by conducting various subgroup analyses. For a stronger empirical evidence of 325 Ivermectin's efficacy, we excluded studies which did not meet the rigor of true RCTs in the 326 'RCTs' subgroup for a 'high' rated level of evidence as per the GRADEpro tool⁵². The GRADE 327 framework is known to be the most widely used assessment to rate quality of evidence⁵². 328 Sensitivity analyses were performed when results were statistically weak. Moreover, we 329 330 performed qualitative analyses to incorporate data from uncontrolled studies.

17

331 Limitations

332 Our results are to be interpreted carefully bearing in mind that we included several nonpeer-reviewed articles to obtain the latest data. We cannot preclude the possibility of unreported 333 334 biases and confounders that could have been recognized by a peer-review process. Furthermore, there was significant heterogeneity in treatment protocols used for dosage, duration, route of 335 administration in interventional and control group. Our analyses may not have accounted for 336 337 confounding by concomitant therapy. Patient demographics and outcome measures varied among 338 different studies. Few studies documented the inclusion of patients <18 years of age. However, 339 the mean/median, dispersion values consistently suggested a predominantly adult population. The clinical classification for severity was inconsistent across the included studies. Most studies 340 were conducted on patients with mild /moderate presentation, which limits the generalizability of 341 342 our results. There was insufficient data regarding the time of treatment in the course of the 343 disease, hence inferences could not be made in that regard. We could not confirm adequate 344 control-matching in some observational studies. We advise discretion in interpretation of our 345 results for adverse-event rate since most of the reported adverse-effects could not be measured objectively by investigators. Because most of the studies were conducted in developing nations, 346 not everyone underwent RT-PCR testing owing to limited resources; clinical diagnosis was used 347 348 instead. Even though RT-PCR is the gold standard for diagnosis, it is subject to its limitations. By virtue of its design, we postulate that this meta-analysis formulated with a random-effects 349 model may have addressed some of the heterogeneity stemming from the above factors. Lastly, 350 we must acknowledge the subjective nature of the GRADE tool used to evaluate the level of 351 evidence⁵². 352

18

353 Current status of Ivermectin

In February 2021, the NIH withdrew its recommendation against using Ivermectin for 354 COVID-19¹⁰¹. Around the same time, WHO shared that they will thoroughly evaluate the 355 available and upcoming evidence on Ivermectin before announcing any change in guidelines¹⁰². 356 As of March 5,2021, the FDA has warned people against using Ivermectin for COVID- 19^{103} , 357 specifically against self-medicating with veterinary Ivermectin formulations^{103,104}. They are vet 358 359 to review the evidence but have initiated a preliminary research. Recently, the EMA (European 360 Medicines Agency) stated that Ivermectin cannot be recommended for the prevention or treatment of COVID-19 outside clinical trials¹⁰⁵. 361

362 Conclusion

In summary, Ivermectin may have a role as an adjuvant treatment in decreasing mortality 363 in mildly/moderately ill COVID-19 patients. Also, lower odds of ICU admissions and use of 364 mechanical ventilation with Ivermectin use were noted but with very low evidence. The 365 366 association with adverse events was inconclusive. Using well-designed larger observational studies^{106,107} and clinical trials, we need to investigate Ivermectin's ideal dosage and timing in 367 the disease course, drug interactions and possible synergistic drug combinations to achieve 368 maximum benefit. We propose pragmatic practice embedded platform trials¹⁰⁸ to test this and 369 370 other re-purposed and novel therapies specifically in severe COVID-19 patients and other 371 critically ill patients.

372 **References**

373 1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157-160. 374 2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in 375 376 real time. Lancet Infect Dis. 2020;20(5):533-534. Domecq JP, Lal A, Sheldrick CR, Kumar VK, Boman K, Bolesta S, Bansal V, et al. 377 3. Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support 378 379 Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry. Critical Care Medicine. 9000; Online First. 380 Bansal V, Singh R, Bhurwal A, Rathore S, Kashyap R. 117: Obesity Is a Risk Factor for 381 4. Increased COVID-19 Severity: A Systemic Review and Meta-Regression. Critical Care 382 *Medicine*.49(1):43. 383 5. Menon T, Gandhi SAQ, Tariq W, Sharma R, Sardar S, Arshad AM, Adhikari R, et al. 384 Impact of Chronic Kidney Disease on Severity and Mortality in COVID-19 Patients: A 385 386 Systematic Review and Meta-analysis. Cureus. 2021;13(4). 387 6. Menon T, Sharma R, Kataria S, Sardar S, Adhikari R, Tousif S, Khan H, et al. The 388 Association of Acute Kidney Injury With Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis. Cureus. 2021;13(3). 389 390 7. Singh R, Shiza ST, Saadat R, Dawe M, Rehman U. Association of Guillain-Barre 391 Syndrome With COVID-19: A Case Report and Literature Review. Cureus. 392 2021;13(3):e13828. 8. Menon T, Sharma R, Earthineni G, Iftikhar H, Sondhi M, Shams S, Khurshid Ahmed N, 393 394 et al. Association of Gastrointestinal System With Severity and Mortality of COVID-19: 395 A Systematic Review and Meta-Analysis. Cureus. 2021;13(2):e13317. 396 9. Razonable RR, Pennington KM, Meehan AM, Wilson JW, Froemming AT, Bennett CE, 397 Marshall AL, et al. A Collaborative Multidisciplinary Approach to the Management of 398 Coronavirus Disease 2019 in the Hospital Setting. Mayo Clin Proc. 2020;95(7):1467-399 1481. 10. Rathore SS, Rojas GA, Sondhi M, Pothuru S, Pydi R, Kancherla N, Singh R, et al. 400 401 Myocarditis associated with Covid-19 disease: a systematic review of published Case 402 reports and Case series. Preprints; 2021/02/01/ 2021. 11. Sheraton M, Deo N, Kashyap R, Surani S. A Review of Neurological Complications of 403 404 COVID-19. Cureus. 2020;12(5):e8192. Khan H, Sabzposh H, Deshpande S, Kashyap R. Pregnancy during COVID-19 405 12. pandemic-Maternal and neonatal outcomes: A concise review. International Journal of 406 Academic Medicine. 2020;6(4):287. 407 Shah K, Mann S, Singh R, Bangar R, Kulkarni R. Impact of COVID-19 on the Mental 408 13. 409 Health of Children and Adolescents. Cureus. 2020;12(8):e10051. 410 14. Sheraton M, Deo N, Dutt T, Surani S, Hall-Flavin D, Kashyap R. Psychological effects of the COVID 19 pandemic on healthcare workers globally: A systematic review. 411 Psychiatry Res. 2020;292:113360. 412 Singh R, Kashyap R, Hutton A, Sharma M, Surani S. A Review of Cardiac 413 15. Complications in Coronavirus Disease 2019. Cureus. 2020;12(5):e8034. 414

415 16. Bhalala U, Gist K, Tripathi S, Chiotos K, Dapul H, Gharpure V, Bansal V, et al. 145: 416 Pediatric COVID-19: A Report From Viral Infection and Respiratory Illness Universal Study (VIRUS). Critical Care Medicine.49(1):58. 417 418 17. Tripathi S, Gist K, Chiotos K, Dapul H, Gharpure V, Bansal V, Kumar V, et al. 61: Risk Factors for Severe COVID-19 Illness in Children: Analysis of the VIRUS: COVID-19 419 420 Registry. Critical Care Medicine.49(1):32. 421 18. Md Insiat Islam R. Current Drugs with Potential for Treatment of COVID-19: A Literature Review. J Pharm Pharm Sci. 2020;23(1):58-64. 422 19. Gilzad-Kohan H, Jamali F. Anti-Inflammatory Properties of Drugs Used to Control 423 424 COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2. J Pharm Pharm Sci. 2020;23:259-277. 425 20. Bansal V, Mahapure KS, Mehra I, Bhurwal A, Tekin A, Singh R, Gupta I, et al. Mortality 426 427 Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Medicine. 2021;8:250. 428 21. Singh R, Rathore SS, Khan H, Bhurwal A, Sheraton M, Ghosh P, Anand S, et al. 429 430 Mortality and Severity in COVID-19 Patients on ACEIs & ARBs-A Meta-Regression 431 Analysis. medRxiv. 2021. 22. Mahmud S, Nagraj S, Karia R, Karale S, Akku R, Mehra I, Joshi A, et al. 140: Efficacy 432 and Safety of Tocilizumab in Hospitalized COVID-19 Patients: A Systematic Review. 433 434 Critical Care Medicine. 2021;49(1):55. Bansal V, Mahapure KS, Bhurwal A, Gupta I, Hassanain S, Makadia J, Madas N, et al. 435 23. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. 436 Front Med (Lausanne). 2020;7:606429. 437 24. Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and 438 439 exceed expectations. J Antibiot (Tokyo). 2017;70(5):495-505. 440 25. Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, Sah R, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol 441 Antimicrob. 2020;19(1):23. 442 443 26. Lundberg L, Pinkham C, Baer A, Amaya M, Narayanan A, Wagstaff KM, Jans DA, et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells 444 and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res. 445 446 2013;100(3):662-672. 27. Tay MY, Fraser JE, Chan WK, Moreland NJ, Rathore AP, Wang C, Vasudevan SG, et al. 447 Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection 448 against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res. 2013;99(3):301-449 450 306. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific 451 28. 452 inhibitor of importin α/β -mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443(3):851-856. 453 29. DiNicolantonio JJ, Barroso J, McCarty M, Ivermectin may be a clinically useful anti-454 inflammatory agent for late-stage COVID-19. Open Heart. 2020;7(2). 455 30. Zhang X, Song Y, Ci X, An N, Ju Y, Li H, Wang X, et al. Ivermectin inhibits LPS-456 induced production of inflammatory cytokines and improves LPS-induced survival in 457 mice. Inflamm Res. 2008;57(11):524-529. 458

459	31.	Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug
460		ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res.
461		2020;178:104787.
462	32.	Gorial FI, Mashhadani S, Sayaly HM, Dakhil BD, AlMashhadani MM, Aljabory AM,
463		Abbas HM, et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19
464		Management (Pilot Trial). medRxiv. 2020:2020.2007.2007.20145979.
465	33.	Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is
466		Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease
467		2019: The Ivermectin in COVID Nineteen Study. Chest. 2021;159(1):85-92.
468	34.	Bhattacharya R, Ray I, Mukherjee R, Chowdhury S, Kulshrestha M, Ghosh R.
469		Observational Study on Clinical Features, Treatment and Outcome of COVID 19 in a
470		tertiary care Centre in India- a retrospective case series. IJSR. 2020;9(10):1-3.
471	35.	Chowdhury ATMM, Shahbaz M, Karim MR, Islam J, Dan G, He S. A Comparative
472		Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on
473		COVID-19 Patients. <i>EJMO</i> . 2021;5(1):63-70.
474	36.	Mega ER. Latin America's embrace of an unproven COVID treatment is hindering drug
475		trials. Nature. 2020;586(7830):481-482.
476	37.	Trial Site Staff. Beyond The Roundup First EU Nation To Approve Ivermectin For
477		Covid-19. https://trialsitenews.com/beyond-the-roundup-first-eu-nation-to-approve-
478		ivermectin-for-covid-19/. Published January 30, 2021. Accessed 02.14.2021.
479	38.	Nayar S, Khanna P, Anand P, Soni NK, Tyagi N, Dubey Y, Patanwar S, et al. Ivermectin
480		in Covid-19: Review of the Current Evidence. The Indian Practitioner. 2021;74(3):27-
481		33.
482	39.	AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring Group (Dte.GHS).
483		CLINICAL GUIDANCE FOR MANAGEMENT OF ADULT COVID-19 PATIENTS.
484		Ministry of Health & Family Welfare, Government of India.
485		https://www.mohfw.gov.in/pdf/COVID19ManagementAlgorithm22042021v1.pdf.
486		Published 2021. Updated 04/22/2021. Accessed 04/25/2021.
487	40.	Chamie-Quintero JJ, Hibberd J, Scheim D. Sharp reductions in COVID-19 case fatalities
488		and excess deaths in Peru in close time conjunction, state-by-state, with ivermectin
489		treatments. State-By-State, with Ivermectin Treatments (January 12, 2021). 2021.
490	41.	Yagisawa M, Foster PJ, Hanaki H, Ōmura S. Global trends in clinical studies of
491		ivermectin in COVID-19. THE JAPANESE JOURNAL OF ANTIBIOTICS. 2021;74:1.
492	42.	Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 Therapy with
493		Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient
494		Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated
495		Patients. medRxiv. 2020.
496		
450	43.	Lima-Morales R, Mendez-Hernandez P, Flores YN, Osorno-Romero P, Cuecuecha-
497	43.	Rugerio E, Nava-Zamora A, Hernandez-Galdamez DR, et al. Effectiveness of a
	43.	
497	43.	Rugerio E, Nava-Zamora A, Hernandez-Galdamez DR, et al. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19
497 498	43.	Rugerio E, Nava-Zamora A, Hernandez-Galdamez DR, et al. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. <i>Int J Infect Dis.</i> 2021;105:598-605.
497 498 499	43.44.	Rugerio E, Nava-Zamora A, Hernandez-Galdamez DR, et al. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. <i>Int J Infect Dis.</i> 2021;105:598-605. Niaee MS, Gheibi N, Namdar P, Allami A, Zolghadr L, Javadi A, Karampour A, et al.
497 498 499 500		Rugerio E, Nava-Zamora A, Hernandez-Galdamez DR, et al. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. <i>Int J Infect Dis.</i> 2021;105:598-605.

 Berry F, Softic L, et al. Oral ivermectin for a scabies outbreak in a long-term-care facility: Potential value in preventing COVID-19 and associated mortality? <i>Br J</i> <i>Dermatol.</i> 2021. The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.4 for Windows. Oxford, England: The Cochrane Collaboration. https://training.cochrane.org/online-learning/core-software-cochrane. reviews/revman/revman-5-download. Published 2020. Accessed 01/31/2021. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ 2013. https://www.meta- analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. <i>Cochrane</i> <i>handbook for systematic reviews of interventions.</i> John Wiley & Sons; 2019. Available from: Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ.</i> 2011;343:d5928. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Janna.</i> 2002;287(22):2973-2982. National Heart L, and Blood Institute Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October.</i> 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478.</i> 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumi	504	45.	Bernigaud C, Guillemot D, Ahmed-Belkacem A, Grimaldi-Bensouda L, Lespine A,
 facility: Potential value in preventing COVID-19 and associated mortality? <i>Br J</i> <i>Dermatol.</i> 2021. for Windows. Oxford, England: The Cochrane Collaboration. https://training.cochrane.org/online-learning/core-software-cochrane- reviews/revman/revman-5-download. Published 2020. Accessed 01/31/2021. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ 2013. https://www.meta- analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. <i>Cochrane handbook for systematic reviews of interventions</i>. John Wiley & Sons; 2019. Available from: Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jana</i>. 2002;287(22):2973-2982. Shational Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. 	505		Berry F, Softic L, et al. Oral ivermectin for a scabies outbreak in a long-term-care
 Dermatol. 2021. The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.4 for Windows. Oxford, England: The Cochrane Collaboration. https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman.5-download. Published 2020. Accessed 01/31/2021. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3. Biostat. Englewood, NJ 2013. https://www.meta-analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019. Available from: Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. Jama. 2002;287(22):2973-2982. National Heart L, and Blood Institute. Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Updated 04/14/2021. Accessed 04/14/2021. 2020. Schütneman H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. Available at SSRN 3734478. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216. Ala	506		facility: Potential value in preventing COVID-19 and associated mortality? Br J
 5.4 for Windows. Oxford, England: The Cochrane Collaboration. https://training.cochrane.org/online-learning/core-software-cochrane. reviews/revman/revman-5-download. Published 2020. Accessed 01/31/2021. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ 2013. https://www.meta- analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019. Available from: 49. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. 50. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. Jama. 2002;287(22):2973-2982. 51. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. 52. Schüneman H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October. 2013;2013. 53. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. Available at SSRN 3734478. 2020. 54. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216. 55. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin R	507		
 5.4 for Windows. Oxford, England: The Cochrane Collaboration. https://training.cochrane.org/online-learning/core-software-cochrane. reviews/revman/revman-5-download. Published 2020. Accessed 01/31/2021. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ 2013. https://www.meta- analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019. Available from: 49. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. 50. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. Jama. 2002;287(22):2973-2982. 51. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. 52. Schüneman H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October. 2013;2013. 53. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. Available at SSRN 3734478. 2020. 54. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216. 55. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin R	508	46.	The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version
 https://training.cochrane.org/online-learning/core-software-cochrane- reviews/revman/revman-5-download, Published 2020. Accessed 01/31/2021. 47. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ 2013. https://www.meta- analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021. 48. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019. Available from: 49. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ.</i> 2011;343:d5928. 50. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama.</i> 2002;287(22):2973-2982. 51. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. 52. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October.</i> 2013;2013. 53. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478.</i> 2020. 54. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis.</i> 2021;103:214-216. 55. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ive	509		
 reviews/revman/revman-5-download, Published 2020. Accessed 01/31/2021. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ 2013. https://www.meta- analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019. Available from: Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama</i>. 2002;287(22):2973-2982. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukaram MS, Peracha MY, Ishaq K, Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>, 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15.			
 47. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 3. Biostat, Englewood, NJ 2013. https://www.meta- analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021. 48. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019. Available from: 49. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. 50. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama</i>. 2002;287(22):2973-2982. 51. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. 52. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. 53. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. 54. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. 55. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. 56. Babalola OE, Bode CO, Ajayi AA, Al			
 Biostat, Englewood, NJ 2013. https://www.meta- analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019. Available from: Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama</i>. 2002;287(22):2973-2982. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brozek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. Available at SSRN 3734478. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. Journal of Bangladesh College of Physicians and Surgeons. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase E, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVIID-19 A randomised control		47.	
 analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019. Available from: Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. So. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jana</i>. 2002;287(22):2973-2982. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. <u>https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools</u>. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qim</i>. 2021. Bud			
 Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019. Available from: Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama</i>. 2002;287(22):2973-2982. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brožek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qim</i>. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh			
 handbook for systematic reviews of interventions. John Wiley & Sons; 2019. Available from: 49. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. 50. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama</i>. 2002;287(22):2973-2982. 51. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. 52. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. 53. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. 54. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. 55. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. 56. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qim</i>. 2021. 57. Budh		48.	
 from: from: Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. 50. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama</i>. 2002;287(22):2973-2982. 51. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. <u>https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools</u>. Updated 04/14/2021. Accessed 04/14/2021, 2020. 52. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. 53. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. 54. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. 55. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. 56. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qim</i>. 2021. 57. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			
 Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama</i>. 2002;287(22):2973-2982. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brozek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Vermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm</i>. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			
 The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. <i>BMJ</i>. 2011;343:d5928. S0. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama</i>. 2002;287(22):2973-2982. S1. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated October</i>. 2013;2013. S3. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm</i>. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		49	
 2011;343:d5928. 50. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama.</i> 2002;287(22):2973-2982. 51. National Heart L, and Blood Institute, Development and Use of Study Quality Assessment Tools. <u>https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools</u>. Updated 04/14/2021. Accessed 04/14/2021, 2020. 52. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. 53. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. 54. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. 55. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. 56. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm</i>. 2021. 57. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			
 50. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama</i>. 2002;287(22):2973-2982. 51. National Heart L, and Blood Institute,. Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. 52. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. 53. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. 54. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. 55. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. 56. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm</i>. 2021. 57. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			e
 Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. <i>Jama</i>. 2002;287(22):2973-2982. National Heart L, and Blood Institute,. Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm</i>. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		50.	
 randomized controlled trials. <i>Jama.</i> 2002;287(22):2973-2982. National Heart L, and Blood Institute,. Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October.</i> 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478.</i> 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis.</i> 2021;103:214-216. Aam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons.</i> 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm.</i> 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			
 National Heart L, and Blood Institute,. Development and Use of Study Quality Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. Available at SSRN 3734478. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. Journal of Bangladesh College of Physicians and Surgeons. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et I. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. Qjm. 2021. 			1 5
 Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment- tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm</i>. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		51.	
 tools. Updated 04/14/2021. Accessed 04/14/2021, 2020. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated</i> <i>October</i>. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm</i>. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		011	
 Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. Available at SSRN 3734478. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. Journal of Bangladesh College of Physicians and Surgeons. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. Qjm. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			
 evidence and the strength of recommendations using the GRADE approach. Updated October. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. Available at SSRN 3734478. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. Journal of Bangladesh College of Physicians and Surgeons. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. Qjm. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		52	1
 October. 2013;2013. Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm</i>. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		021	
 Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478</i>. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis</i>. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. Qjm. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			
 Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478.</i> 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis.</i> 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons.</i> 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm.</i> 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		53.	
 Available at SSRN 3734478. 2020. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. Qjm. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			
 54. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis.</i> 2021;103:214-216. 55. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons.</i> 2020;38(0):10-15. 56. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. Qjm. 2021. 57. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			
 A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis.</i> 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons.</i> 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. Qjm. 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		54	
 of illness. <i>Int J Infect Dis.</i> 2021;103:214-216. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. <i>Journal of Bangladesh College of Physicians and Surgeons.</i> 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm.</i> 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		511	
 536 55. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 537 COVID-19 positive patients treated with combination of ivermectin and doxycycline. 538 <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. 539 56. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et 540 al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised 541 controlled double-blind, dose-response study in Lagos. <i>Qjm.</i> 2021. 542 57. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			
 537 COVID-19 positive patients treated with combination of ivermectin and doxycycline. 538 <i>Journal of Bangladesh College of Physicians and Surgeons</i>. 2020;38(0):10-15. 539 56. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et 540 al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised 541 controlled double-blind, dose-response study in Lagos. <i>Qjm</i>. 2021. 542 57. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		55	
 Journal of Bangladesh College of Physicians and Surgeons. 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm.</i> 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			
 539 56. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, Salu OB, et 540 al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised 541 controlled double-blind, dose-response study in Lagos. <i>Qjm.</i> 2021. 542 57. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 			1 1 7
 al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>Qjm.</i> 2021. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		56	
 541 controlled double-blind, dose-response study in Lagos. <i>Qjm.</i> 2021. 542 57. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical 		50.	
542 57. Budhiraja S, Soni A, Jha V, Indrayan A, Dewan A, Singh O, Singh YP, et al. Clinical			
		57	
543 Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the		011	Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the
544 Correlates of their Mortality: An Indian Experience. <i>medRxiv</i> .			
545 2020:2020.2011.2016.20232223.			
546 58. Bukhari KHS, Asghar A, Perveen N, Hayat A, Mangat SA, Butt KR, Abdullah M, et al.		58	
547 Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease. <i>medRxiv</i> .		20.	
548 2021:2021.2002.2002.21250840.			

549 59. Camprubi D, Almuedo-Riera A, Marti-Soler H, Soriano A, Hurtado JC, Subira C, Grau-550 Pujol B, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One. 2020;15(11):e0242184. 551 552 60. Carvallo H, Roberto H, Eugenia FM. Safety and Efficacy of the combined use of 553 ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. medRxiv. 554 2020:2020.2009.2010.20191619. 555 61. Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, Richardson MA, et al. The effect of early treatment with ivermectin on viral 556 load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, 557 558 double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021:100720. 559 62. Chachar AZK, Khan KA, Asif M, Tanveer K, Khaqan A, Basri R. Effectiveness of 560 Ivermectin in SARS-CoV-2/COVID-19 Patients. International Journal of Sciences. 561 2020;9(09):31-35. 562 63. Elalfy H, Besheer T, El-Mesery A, El-Gilany AH, Soliman MA, Alhawarey A, Alegezy 563 M, et al. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc 564 565 supplement (MANS.NRIZ study) on the clearance of mild COVID-19. J Med Virol. 2021;93(5):3176-3183. 566 Elgazzar A, Hany B, Youssef SA, Hafez M, Moussa H, eltaweel A. Efficacy and Safety 567 64. of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. Research Square. 568 569 2020. Espitia-Hernandez G, Munguia L, Diaz-Chiguer D, López-Elizalde R, Jimenez-Ponce F. 570 65. Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 571 infected patients: A proof of concept study. Biomedical Research. 2020;31(5):129-133. 572 66. Galan LEB, Santos NMD, Asato MS, Araujo JV, de Lima Moreira A, Araujo AMM, 573 574 Paiva ADP, et al. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. 575 Pathog Glob Health. 2021:1-8. 576 577 67. Gonzalez JLB, Gámez MG, Enciso EAM, Maldonado RJE, Palacios DH, Campos SD, Robles IO, et al. Efficacy and safety of Ivermectin and Hydroxychloroquine in patients 578 with severe COVID-19. A randomized controlled trial. medRxiv. 2021. 579 580 68. Guzmán MJM, Castillo-Gonzalez A, Gonzalez JLB, Gámez MG, Enciso EAM, Robles IO, Díaz ALG, et al. Factors associated with increased mortality in critically ill COVID-581 19 patients in a Mexican public hospital: the other faces of health system oversaturation. 582 medRxiv. 2021. 583 69. Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS. 584 Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating 585 COVID-19 patients in Baghdad, Iraq. medRxiv. 2020:2020.2010.2026.20219345. 586 Hussain SMA, Shuayb M, Rahman M. Outcome of ivermectin and doxycycline in cancer 587 70. patients with COVID-19: A positive experience in Bangladesh. International Journal of 588 Molecular & Immuno Oncology. 2021;6(1):27-29. 589 590 71. Khan MSI, Khan MSI, Debnath CR, Nath PN, Mahtab MA, Nabeka H, Matsuda S, et al. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Arch 591 Bronconeumol. 2020;56(12):828-830. 592

72. Ravikirti, Roy R, Pattadar C, Raj R, Agarwal N, Biswas B, Majhi PK, et al. Ivermectin as 593 594 a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial. medRxiv. 2021:2021.2001.2005.21249310. 595 596 73. Kishoria N, Mathur SL, Parmar V, Kaur RJ, Agarwal H, Parihar BS, Verma S. IVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS 597 598 RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: RESULTS OF AN 599 OPEN-LABEL RANDOMIZED CLINICAL STUDY. Paripex Indian Journal of Research. 2020;9(8):1-4. 600 74. Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, Solari R, 601 602 et al. Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial. SSRN Electronic Journal. 2020. 603 75. Lopez-Medina E, Lopez P, Hurtado IC, Davalos DM, Ramirez O, Martinez E, 604 605 Diazgranados JA, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. Jama. 2021;325(14):1426-606 607 1435. 608 76. Mahmud R. Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of 609 Confirmed Covid-19 Infection. Dhaka Medical College Bangladesh. https://clinicaltrials.gov/ct2/show/study/NCT04523831. Published 2020. Updated 610 October 9, 2020. Accessed 02.14.2021. 611 Mohan A, Tiwari P, Suri T, Mittal S, Patel A, Jain A, T V, et al. Ivermectin in mild and 612 77. moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial. Research 613 *Square*. 2021. 614 78. Morgenstern J, Redondo JN, De Leon A, Canela JM, Torres N, Tavares J, Minava M, et 615 al. The use of compassionate Ivermectin in the management of symptomatic outpatients 616 and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center 617 618 Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020. J Clin Trials. 2020;11(S9):1-4. 619 79. Núñez AC, Gutierrez T, Cervantes JML, Juarez M, Yuca GG, Murcia APR, Martínez JJ. 620 621 Therapeutic Efficacy of Ivermectin as an Adjuvant in the Treatment of Patients with COVID-19. International Journal of Innovative Science and Research Technology. 622 2020;5(7):211-215. 623 Okumuş N, Demirtürk N, ÇEtİNkaya RA, GÜNer R, Avcı İY, Orhan S, Konya P, et al. 624 80. Evaluation of the Effectiveness and Safety of Adding Ivermectin to Treatment in Severe 625 COVID-19 Patients. Research Square. 2021(02.14.2021). 626 81. Pott-Junior H, Bastos Paoliello MM, Miguel AQC, da Cunha AF, de Melo Freire CC, 627 Neves FF, da Silva de Avo LR, et al. Use of ivermectin in the treatment of Covid-19: A 628 pilot trial. Toxicol Rep. 2021;8(0):505-510. 629 630 82. Soto-Becerra P, Culquichicón C, Hurtado-Roca Y, Araujo-Castillo RV. Real-world 631 effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a 632 nationwide healthcare system in Peru. medRxiv. 2020. 633 83. Spoorthi V, Sasank S. Utility of ivermectin and doxycycline combination for the 634 treatment of SARS-CoV2. IAIM. 2020;7(10):177-182. 635 84. Carvallo H. Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 636 637 19 - Study Results - ClinicalTrials.gov.

638		https://clinicaltrials.gov/ct2/show/results/NCT04425863?view=results. Published 2020.
639	~ ~	Updated 10/19/2020. Accessed 02/12/2021.
640	85.	Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add
641		on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci.
642		2020;23:462-469.
643	86.	Hill A, Abdulamir A, Ahmed S, Asghar A, Babalola OE, Basri R, Chaccour C, et al.
644		Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection.
645		Research Square. 2021.
646	87.	Lawrie T. Ivermectin reduces the risk of death from COVID-19 -a rapid review and
647		meta-analysis in support of the recommendation of the Front Line COVID-19 Critical
648		Care Alliance. (Latest version v1.2 - 6 Jan 2021). 2021. Available from:
649	88.	Nardelli P, Zangrillo A, Sanchini G, Likhvantsev VV, Yavorovskiy AG, Garcia CSR,
650		Landoni G. Crying wolf in time of Corona: the strange case of ivermectin and
651		hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment
652		from clinical use? Signa Vitae. 2021;1:2.
653	89.	Kow CS, Merchant HA, Mustafa ZU, Hasan SS. The association between the use of
654		ivermectin and mortality in patients with COVID-19: a meta-analysis. <i>Pharmacol Rep.</i>
655		2021:1-7.
656	90.	Bryant A, Lawrie TA, Dowswell T, Fordham E, Mitchell S, Hill S, Tham T. Ivermectin
657	201	for Prevention and Treatment of COVID-19 Infection: a Systematic Review and Meta-
658		analysis. <i>Research Square</i> . 2021.
659	91.	British Ivermectin Recommendation Development. The BIRD Recommendation on the
660	<i>)</i> 1.	Use of Ivermectin for Covid-19. <u>https://www.francesoir.fr/sites/francesoir/files/media-</u>
661		icons/bird-proceedings-02-03-2021-v151.pdf. Published 2021. Accessed 04.01.2021.
662	92.	Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of
663	12.	pharmacological interventions for the treatment of COVID-19: A systematic review and
664		network meta-analysis. <i>PLoS Med.</i> 2020;17(12):e1003501.
665	93.	Castañeda-Sabogal A, Chambergo-Michilot D, Toro-Huamanchumo CJ, Silva-Rengifo
666	93.	C, Gonzales-Zamora J, Barboza JJ. Outcomes of Ivermectin in the treatment of COVID-
		19: a systematic review and meta-analysis. <i>medRxiv</i> . 2021;2021.2001.2026.21250420.
667	04	
668	94.	World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. WHO.
669	05	https://covid19.who.int/. Updated 02.14.2021. Accessed 02.14.2021.
670	95.	Abate SM, Ahmed Ali S, Mantfardo B, Basu B. Rate of Intensive Care Unit admission
671		and outcomes among patients with coronavirus: A systematic review and Meta-analysis.
672	0.6	<i>PLoS One.</i> 2020;15(7):e0235653.
673	96.	Elsayed HH, Hassaballa AS, Ahmed TA, Gumaa M, Sharkawy HY. Variation in outcome
674		of invasive mechanical ventilation between different countries for patients with severe
675	. –	COVID-19: a systematic review and meta-analysis. 2020.
676	97.	Richardson S. Presenting characteristics, comorbidities, and outcomes among 5700
677		patients hospitalized with COVID-19 in the New York City area (published online ahead
678		of print, 2020 Apr 22). Jama.
679	98.	Yousaf Z, Al-Shokri SD, Al-Soub H, Mohamed MFH. COVID-19-associated SIADH: a
680		clue in the times of pandemic! Am J Physiol Endocrinol Metab. 2020;318(6):E882-E885.
681	99.	Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, et
682		al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med.
683		2020;383(19):1813-1826.


684	100.	Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, et al.
685		Association Between Administration of Systemic Corticosteroids and Mortality Among
686		Critically Ill Patients With COVID-19: A Meta-analysis. Jama. 2020;324(13):1330-1341.
687	101.	National Institutes of Health. Ivermectin COVID-19 Treatment Guidelines. National
688		Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/antiviral-
689		therapy/ivermectin/. Published 2020. Updated February 11, 2021. Accessed 02.14.2021.
690	102.	Trial Site Staff. WHO's Dr. Maria Van Kerkhove: Ivermectin 'Has Shown Promising
691		Results in Some Trials'. Trial News. <u>https://trialsitenews.com/whos-dr-maria-van-</u>
692		kerkhove-ivermectin-has-shown-promising-results-in-some-trials/. Published 2021.
693		Updated February 6, 2021. Accessed 02.14.2021.
694	103.	FDA. FAQ: COVID-19 and Ivermectin Intended for Animals FDA. FDA.
695		https://www.fda.gov/animal-veterinary/product-safety-information/faq-covid-19-and-
696		ivermectin-intended-animals. Published 2020. Updated 12/16/2020. Accessed
697		02.14.2021.
698	104.	FDA. Why You Should Not Use Ivermectin to Treat or Prevent COVID-19 FDA.
699		https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-
700		treat-or-prevent-covid-19. Published 2021. Updated 03.05.2021. Accessed 04.10.2021.
701	105.	European Medicines Agency. EMA advises against use of ivermectin for the prevention
702		or treatment of COVID-19 outside randomised clinical trials European Medicines
703		Agency. https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-
704		prevention-treatment-covid-19-outside-randomised-clinical-trials. Published 2021.
705		Updated 03.22.2021. Accessed 04.10.2021.
706	106.	Walkey AJ, Sheldrick RC, Kashyap R, Kumar VK, Boman K, Bolesta S, Zampieri FG, et
707		al. Guiding Principles for the Conduct of Observational Critical Care Research for
708		Coronavirus Disease 2019 Pandemics and Beyond: The Society of Critical Care
709		Medicine Discovery Viral Infection and Respiratory Illness Universal Study Registry.
710		<i>Crit Care Med.</i> 2020;48(11):e1038-e1044.
711	107.	Walkey AJ, Kumar VK, Harhay MO, Bolesta S, Bansal V, Gajic O, Kashyap R. The
712		Viral Infection and Respiratory Illness Universal Study (VIRUS): An International
713		Registry of Coronavirus 2019-Related Critical Illness. Crit Care Explor.
714		2020;2(4):e0113.
715	108.	FDA. FDA experts discuss COVID-19 therapeutic clinical trials American Medical
716		Association. AMA Webinar Series. https://www.ama-assn.org/delivering-care/public-
717		health/fda-experts-discuss-covid-19-therapeutic-clinical-trials. Updated 03/17/2021.
718		Accessed 04/15/2021.

- 720 Figure Legends:
- 721 Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow—
- 722 study inclusion. ICU: Intensive Care Unit, CDC: Centers for Disease Control and
- 723 Prevention, RCT: Randomized controlled trial, WHO: World Health Organization
- 724 Figure 2: Meta-analysis for Ivermectin use and overall Mortality
- 725 Figure 3: Subgroup analysis by study design for Ivermectin use and mortality
- 726 Figure 4: Meta-analysis for Ivermectin use and need for ICU admission and mechanical
- 727 ventilation
- 728 Figure 5: Meta-analysis for Ivermectin use and Adverse effects
- 729 e-figure 1: Sensitivity analysis Mortality- clinical trials (excluded Galan et al)
- rigure 2: Sensitivity analysis Mortality- RCTs (excluded Elgazzar et al)
- rigure 3: Sensitivity analysis Mortality- Observational (excluded Soto-Becerra et al)
- 732 e-figure 4: Subgroup Analysis- Inpatient overall
- raise e-figure 5: Sensitivity Analysis- Inpatient overall (excluded Soto-Becerra et al)
- 734 e-figure 6: Subgroup Analysis- Inpatient by Study Design -RCTs
- 735 e-figure 7: Sensitivity Analysis- Inpatient RCTs (excluded Galan et al)
- 736 e-figure 8: Subgroup Analysis- Inpatient by Study Design -Observational
- ranker 737 e-figure 9: Sensitivity Analysis- Inpatient Observational (excluded Soto-Becerra et al)
- 738 e-figure 10: Pooled Mortality overall
- 739 e-figure 11: Pooled Need for ICU admission
- 740 e-figure 12: Pooled Need for Mechanical Ventilation
- 741 e-figure 13: Pooled adverse event overall
- 742 e-figure 14: Funnel Plot overall mortality

- 743 e-figure 15: Funnel Plot Mortality RCTs-Mild/Moderate COVID-19
- 744 e-figure 16: Funnel Plot Mortality RCTs-Severe COVID-19
- 745 e-figure 17: Funnel Plot Need for ICU Admission
- 746 e-figure 18: Funnel Plot Need for Mechanical Ventilation
- 747 e-figure 19: Funnel Plot Adverse event

748

- 749 e-table 1. Study characteristic table for all included studies
- 750 e-table 2. Cochrane Risk of bias assessment of the trials those were included in the study
- 751 e-table 3. Correlation of quality measures with estimates of treatment effects assessment of
- 752 the trials those were included in the study
- re-table 4. NIH quality assessment Tool for case series those were included in the study
- 754 e-table 5. NIH Quality Assessment of Case-Control Studies
- 755 e-table 6. NIH Quality Assessment of Observational Cohort and Cross-Sectional Studies
- rtable 7. Certainty of the evidence (GRADE) Profile at Outcome Level
- 757 e-table 8. Ongoing clinical trials



Abbreviation: WHO: World Health Organization, CDC: CDC: Centers for Disease Control and Prevention, RCT: Randomized controlled trial, Non-RCT: Non Randomized controlled trial, ICU: Intensive Care Unit

Figure 2A: Meta-analysis for Ivermectin use and Overall Mortality

	lverme	ctin	No lverm	ectin		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Babalola et al	0	42	0	20		Not estimable	
Budhiraja et al	0	34	103	942	3.0%	0.12 [0.01, 1.93]	A
Cadegiani et al	0	110	2	137	2.6%	0.25 [0.01, 5.16]	An
Chaccour et al	0	12	0	12		Not estimable	
Elalfy et al	0	62	0	51		Not estimable	
Elgazzar et al	2	200	24	200	6.1%	0.07 [0.02, 0.32]	
Galan et al	12	53	25	115	8.4%	1.05 [0.48, 2.30]	
Gonzalez et al	5	36	8	70	6.9%	1.25 [0.38, 4.14]	22
Gorial et al	0	16	2	71	2.6%	0.84 [0.04, 18.39]	20
Guzman et al	48	122	39	74	9.0%	0.58 [0.32, 1.04]	
Hashim et al	2	70	6	70	5.5%	0.31 [0.06, 1.61]	Art and a state of the state of
Khan et al	1	115	9	133	4.3%	0.12 [0.02, 0.97]	
Kirti et al	0	55	4	57	2.8%	0.11 [0.01, 2.04]	★;
Lima-Morales et al	13	434	52	287	8.8%	0.14 [0.07, 0.26]	
Lopez-Medina et al	0	200	1	198	2.4%	0.33 [0.01, 8.11]	, a 202 a
Mahmud et al	0	183	3	180	2.7%	0.14 [0.01, 2.69]	★
Mohan et al	0	100	0	52		Not estimable	
Niaee et al	4	120	11	60	6.9%	0.15 [0.05, 0.51]	to the second second second second second second second second second second second second second second second
Okumus et al	6	30	9	30	7.0%	0.58 [0.18, 1.91]	6
Rajter et al	26	173	27	107	8.9%	0.52 [0.29, 0.96]	Contraction of the second second second second second second second second second second second second second s
Soto-Becerra et al	132	561	940	5122	9.8%	1.37 [1.11, 1.68]	
Veerapaneni et al	1	50	0	50	2.4%	3.06 [0.12, 76.95]	
Total (95% CI)		2778		8038	100.0%	0.39 [0.22, 0.70]	•
Total events	252		1265				82

Figure 2B: Overall Mortality-Sensitivity analysis (excluded Soto Becerra et al)

	lverme	ctin	No lverm	nectin		Odds Ratio		Odd	s Ratio	
Study or Subgroup	Events Total		Events Tota		Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl			
Babalola et al	0	42	0	20		Not estimable				
Budhiraja et al	0	34	103	942	2.5%	0.12 [0.01, 1.93]	•			
Cadegiani et al	0	110	2	137	2.2%	0.25 [0.01, 5.16]	<u></u>	1		
Chaccour et al	0	12	0	12		Not estimable				
Elalfy et al	0	62	0	51		Not estimable				
Elgazzar et al	2	200	24	200	6.3%	0.07 [0.02, 0.32]	22	-		
Galan et al	12	53	25	115	10.4%	1.05 [0.48, 2.30]				
Gonzalez et al	5	36	8	70	7.7%	1.25 [0.38, 4.14]				
Gorial et al	0	16	2	71	2.2%	0.84 [0.04, 18.39]	-		<u> </u>	<u></u>
Guzman et al	48	122	39	74	11.8%	0.58 [0.32, 1.04]			-	
Hashim et al	2	70	6	70	5.5%	0.31 [0.06, 1.61]				
Khan et al	1	115	9	133	4.0%	0.12 [0.02, 0.97]	2		-	
Kirti et al	0	55	4	57	2.3%	0.11 [0.01, 2.04]	•			
Lima-Morales et al	13	434	52	287	11.5%	0.14 [0.07, 0.26]				
Lopez-Medina et al	0	200	1	198	2.0%	0.33 [0.01, 8.11]		1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1		
Mahmud et al	0	183	3	180	2.3%	0.14 [0.01, 2.69]	•			
Mohan et al	0	100	0	52		Not estimable				
Niaee et al	4	120	11	60	7.7%	0.15 [0.05, 0.51]				
Okumus et al	6	30	9	30	7.8%	0.58 [0.18, 1.91]				
Rajter et al	26	173	27	107	11.6%	0.52 [0.29, 0.96]			<u> </u>	
Soto-Becerra et al	132	561	940	5122	0.0%	1.37 [1.11, 1.68]				
Veerapaneni et al	1	50	0	50	2.0%	3.06 [0.12, 76.95]				2
Total (95% CI)		2217		2916	100.0%	0.36 [0.22, 0.58]		•		
Total events	120		325							
Heterogeneity: Tau²: Test for overall effect				(P = 0.0	02); I² = 5	6%	L 0.01	0.1 Ivermectin	1 1 1 No Ivermed	

Figure 3A: Subgroup analysis by Study Designs- Clinical trials




Figure 3B: Subgroup analysis by Study Designs- RCTs

	lverme	ctin	No lverm	ectin		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
1.4.1 Mild-Moderate	COVID-19	12				200-0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
Babalola et al	0	42	0	20		Not estimable	
Chaccour et al	0	12	0	12		Not estimable	
Elgazzar et al	0	100	4	100	5.2%	0.11 [0.01, 2.01]	•
Hashim et al	0	48	0	48		Not estimable	
Kirti et al	0	55	4	57	5.2%	0.11 [0.01, 2.04]	• • • • • • • • • • • • • • • • • • •
Lopez-Medina et al	0	200	1	198	4.5%	0.33 [0.01, 8.11]	· · · · · · · · · · · · · · · · · · ·
Mahmud et al	0	183	3	180	5.1%	0.14 [0.01, 2.69]	+ · · · · · · · · · · · · · · · · · · ·
Mohan et al	0	100	0	52		Not estimable	
Niaee et al	1	103	10	55	8.2%	0.04 [0.01, 0.36]	← • • • • • • • • • • • • • • • • • • •
Subtotal (95% CI)		843		722	28.2%	0.10 [0.03, 0.33]	
Total events	1		22				
Heterogeneity: Tau ² :	= 0.00; Chi	² = 1.17	r, df = 4 (P)	= 0.88);	$ ^{2} = 0\%$		
Test for overall effect	: Z= 3.75 (P = 0.0	002)				
1.4.2 Severe/Critical	COVID-19						
Elgazzar et al	2	100	20	100	11.6%	0.08 [0.02, 0.36]	
Galan et al	12	53	25	115	16.6%	1.05 [0.48, 2.30]	
Gonzalez et al	5	36	8	70	13.5%	1.25 [0.38, 4.14]	
Hashim et al	2	22	6	22	10.0%	0.27 [0.05, 1.50]	
Niaee et al	3	17	1	5	6.4%	0.86 [0.07, 10.67]	
Okumus et al	6	30	9	30	13.6%	0.58 [0.18, 1.91]	
Subtotal (95% CI)		258		342	71.8%	0.53 [0.23, 1.23]	
Total events	30		69				
Heterogeneity: Tau ² :	= 0.59; Chi	² = 11.7	75, df = 5 (l	P = 0.04); I ^z = 579	6	
Test for overall effect	: Z = 1.48 (P = 0.1	4)				
Total (95% CI)		1101		1064	100.0%	0.33 [0.15, 0.72]	-
Total events	31		91				
Heterogeneity: Tau ² :	= 0.79; Chi	² = 21.4	45, df = 10	(P = 0.0)	2); I ² = 53	196	
Test for overall effect							0.01 0.1 i 10 100 Ivermectin No Ivermectin
Test for subgroup dif				(P = 0.0)	12) IF = 81	13%	ivermecun No ivermecun

Figure 3C: Subgroup analysis by Study Designs- Observational

	lverme	ctin	No lverm	ectin		Odds Ratio		Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rando	om, 95% Cl	
Budhiraja et al	0	34	103	942	5.1%	0.12 [0.01, 1.93]	4	•		
Cadegiani et al	0	110	2	137	4.4%	0.25 [0.01, 5.16]				
Guzman et al	48	122	39	74	24.7%	0.58 [0.32, 1.04]				
Khan et al	1	115	9	133	8.1%	0.12 [0.02, 0.97]				
Rajter et al	26	173	27	107	24.4%	0.52 [0.29, 0.96]				
Soto-Becerra et al	132	561	940	5122	29.2%	1.37 [1.11, 1.68]			-	
Veerapaneni et al	1	50	0	50	4.0%	3.06 [0.12, 76.95]		27	•	
Total (95% CI)		1165		6565	100.0%	0.61 [0.30, 1.22]		-	-	
Total events	208		1120							
Heterogeneity: Tau ² = Test for overall effect:				P = 0.00	08); I² = 74	4%	0.01	0.1 1 Ivermectin	10 No Ivermectin	100

Figure 4A: Meta-analysis for Ivermectin use and need for ICU admission

	Ivermectin No Ivermectin					Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
Khan et al	1	115	11	133	15.3%	0.10 [0.01, 0.77]	
Pott-Jinior et al	1	27	1	4	9.1%	0.12 [0.01, 2.36]	+ · · · · · · · · · · · · · · · · · · ·
Camprubi et al	5	13	9	13	19.7%	0.28 [0.05, 1.41]	
Kirti et al	5	55	6	57	24.4%	0.85 [0.24, 2.96]	
Galan et al	15	53	25	115	31.4%	1.42 [0.68, 2.99]	
Total (95% CI)		263		322	100.0%	0.48 [0.17, 1.37]	
Total events	27		52				100 12.000000
Heterogeneity: Tau ² =	= 0.77; Ch	² = 9.73	7, df = 4 (P	= 0.04);	I ² = 59%		the stand of the second
Test for overall effect:	Z=1.37 ((P = 0.1	7)				0.01 0.1 1 10 100 Favours [experimental] Favours [control]

Figure 4B: Sensitivity-analysis (excluded Galan et al)

Study or Subgroup	Ivermectin No Ivermectin					Odds Ratio	Odds Ratio
	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Khan et al	1	115	11	133	20.3%	0.10 [0.01, 0.77]	
Pott-Jinior et al	1	27	1	4	10.7%	0.12 [0.01, 2.36]	← +
Camprubi et al	5	13	9	13	28.9%	0.28 [0.05, 1.41]	
Kirti et al	5	55	6	57	40.1%	0.85 [0.24, 2.96]	
Galan et al	15	53	25	115	0.0%	1.42 [0.68, 2.99]	
Total (95% CI)		210		207	100.0%	0.32 [0.11, 0.92]	-
Total events	12		27				
Heterogeneity: Tau ² =	= 0.31; Chi	² = 4.09	9, df = 3 (P	= 0.25);	I² = 27%		
Test for overall effect							0.01 0.1 1 10 100 Favours [experimental] Favours [control]

Figure 4C: Meta-analysis for Ivermectin use and need for Mechanical Ventilation

	lverme	ctin	No lverm	octin		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-II, Random, 95% CI		M-II, Random, 95% CI	
Cadegiani et al	0	110	9	137	2.7%	0.06 [0.00, 1.06]	+	•	
Camprubi et al	3	13	5	13	1.1%	0.48 (0.09, 2.65)			
Galan et al	12	53	24	115	25.0%	1.11 [0.51, 2.43]			
Kirti et al	1	55	5	57	4.5%	0.19 [0.02, 1.70]	8		
Kroleweicki et al	1	30	0	15	2.1%	1.58 [0.06, 41.03]		3	2.5
Lima-Morales et al	8	434	11	287	19.9%	0.47 [0.19, 1.19]			
Mohan et al	0	100	0	52		Not estimable			
Pott-Jinior et al	1	27	1	4	2.4%	0.12 [0.01, 2.36]	+		
Rajter et al	36	173	26	107	36.3%	N 82 (N 46, 1 45)			
Total (95% CI)		995		787	100.0%	0.64 [0.40, 1.04]		•	
Total events	62		81					1000	
I leterogeneity: Tau ² =	= 0.00; Chi	² = 0.43), df = 7 (P	= 0.30);	$l^2 = 17\%$		10.04		400
Test for overall effect	Z – 1.81 ((P – 0.0	7)				0.01	0.1 1 10 Ivermectin No Ivermectin	100

Figure 4D: Sensitivity-analysis (excluded Galan et al)

	lverme	ctin	No lverm	ectin		Odds Ratio		Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Rand	om, 95% Cl	
Cadegiani et al	0	110	9	137	3.3%	0.06 [0.00, 1.06]	+		+	
Camprubi et al	3	13	5	13	8.8%	0.48 [0.09, 2.65]				
Galan et al	12	53	24	115	0.0%	1.11 [0.51, 2.43]				
Kirti et al	1	55	5	57	5.5%	0.19 [0.02, 1.70]			-	
Kroleweicki et al	1	30	0	15	2.5%	1.58 [0.06, 41.03]				123
Lima-Morales et al	8	434	11	287	25.9%	0.47 [0.19, 1.19]				
Mohan et al	0	100	0	52		Not estimable				
Pott-Jinior et al	1	27	1	4	2.9%	0.12 [0.01, 2.36]	•			
Rajter et al	36	173	26	107	51.1%	0.82 [0.46, 1.45]				
Total (95% CI)		942		672	100.0%	0.55 [0.33, 0.93]		+		
Total events	50		57							
Heterogeneity: Tau ² =	= 0.05; Chi	² = 6.61	l, df = 6 (P	= 0.36);	I ² = 9%					
Test for overall effect							0.01	0.1 Ivermectin	1 10 No Ivermectin	100

Figure 5A: Meta-analysis for Ivermectin use and Adverse effects




Figure 5B: Sensitivity-analysis (excluded Mahmud et al)

	lverme	ctin	No lvermectin			Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	ents Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Afsar et al	0	41	0	54		Not estimable			
Ahmed et al	0	45	0	23		Not estimable			
Babalola et al	0	42	0	20		Not estimable			
Bukhari et al	0	41	0	45		Not estimable			
Camprubi et al	3	13	4	13	3.2%	0.68 [0.12, 3.87]		S	
Chaccour et al	5	12	5	12	3.7%	1.00 [0.20, 5.07]		3 <u> </u>	
Chowdhury et al	19	60	26	56	16.9%	0.53 [0.25, 1.14]		2 	
Espitia-Hernandez et al	3	28	0	7	1.0%	2.06 [0.10, 44.48]		10 A 2 24	
Galan et al	8	53	16	115	11.5%	1.10 [0.44, 2.76]		27 <u>2</u> 3 <u>2</u> 3	
Gorial et al	0	16	0	71		Not estimable			
Kroleweicki et al	13	30	5	15	5.8%	1.53 [0.42, 5.58]		C	
Lopez-Medina et al	156	200	163	198	39.5%	0.76 [0.46, 1.25]		2	
Mahmud et al	9	185	0	180	0.0%	19.43 [1.12, 336.37]			
Mohan et al	14	100	6	52	9.3%	1.25 [0.45, 3.47]		() () ()	
Okumus et al	0	30	3	30	1.1%	0.13 [0.01, 2.61]	+		
Pott-Jinior et al	7	27	2	4	2.1%	0.35 [0.04, 2.98]	-	<u> 1997 ()</u>	
Veerapaneni et al	8	50	4	50	6.0%	2.19 [0.61, 7.81]		37 <u>-37-38</u> -38	
Total (95% CI)		788		765	100.0%	0.85 [0.62, 1.16]		•	
Total events	236		234					5 - Sec.	
Heterogeneity: Tau ² = 0.0	10; Chi² = 8	8.00, df	= 10 (P = 1	0.63); I ² =	= 0%		0.01	0.1 1 10	4.00
Test for overall effect: Z =	1.01 (P=	0.31)					0.01	lvermectin No lvermectin	100